多发性骨髓瘤治疗进展

Advancements in multiple meyloma therapy

近年来新的治疗药物和手段的应用使多发性骨髓瘤（MM）患者的疗效和预后有了很大改善。脂质体阿霉素有可能代替传统阿霉素成为新的初治患者标准诱导方案的组成部分，靶向性药物蛋白酶体抑制剂硼替佐米已作为二线药物用于对一种治疗方案失败的患者，三氧化二砷（ATO）与抗坏血酸联合在难治性和复发患者中取得一定疗效，二次移植的应用使一部分预后良好的患者生存状况得到改善。

There are several great advancements in the therapy of multiple meyloma （MM） which have improved the outcome of MM patients in recent years. The combined chemotherapy based on pegylated liposomal doxorubicin instead of traditional doxorubicin may become a standard induction regimen in newly diagnosed MM patients. A target antineoplastic agent bortezomib has been used as the second line agent for patients who have failed in the first line therapy. Arsenic trioxide combined with ascorbic acid has been demonstrated its effectiveness in relapsed or refractory MM patients. Tandem autologous transplantation can extend the survival of patients who have low-risk factors.